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Abstract: Chronic oral or systemic nonselective nonsteroidal anti-inflammatory drug (NSAID) 
therapy, ubiquitously used by physicians to treat osteoarthritis-associated pain, is associated with 
a wide range of symptomatic adverse events, the most frequent and serious of which is gastropa-
thy. Although cardiovascular and renal problems are a very real concern, they are significantly 
less frequent. These complications can be life-threatening in at-risk populations such as older 
adults, who are common users of long-term oral systemic NSAID therapy. Topical NSAID 
formulations deliver effective doses of analgesics directly to the affected joints, thereby limit-
ing systemic exposure and potentially the risk of systemic adverse events, such as gastropathy 
and serious cardiovascular events. There are currently two topical NSAIDs approved by the US 
Food and Drug Administration for osteoarthritis-associated pain, as well as for the signs and 
symptoms of osteoarthritis. This review discusses the relative safety, and the gastrointestinal, 
cardiovascular, and renal risks of chronic oral or systemic NSAID therapy and topical NSAID 
formulations in patients with osteoarthritis.
Keywords: NSAIDs, osteoarthritis, topical administration, synovial fluid, peptic ulcer, 
Helicobacter pylori
Introduction
Osteoarthritis is a chronic, degenerative joint disorder characterized by destruction of 
articular cartilage, synovial inflammation, and subchondral bone alterations.1 It is the 
most common type of arthritis, affecting approximately 27 million people in the US.1 
Optimal management of osteoarthritis requires both pharmacologic and nonpharma-
cologic approaches, with nonsteroidal anti-inflammatory drugs (NSAIDs) frequently 
selected as the mainstay of pharmacologic treatment.2 Although NSAIDs may be the 
most effective analgesic for many patients with osteoarthritis, when administered 
orally they confer significant gastrointestinal, cardiovascular, and renal risks.2,3 Elderly 
patients, who constitute the greatest population of patients with osteoarthritis, are at 
high risk for developing gastrointestinal adverse events, that range from mild dys-
pepsia or abdominal discomfort to potentially life-threatening complications, such as 
perforation and hemorrhage.4–6 This range of events, known as “NSAID gastropathy”, 
has been recognized for more than two decades as an important complication of long-
term NSAID treatment. Despite concomitant administration of medications such as 
proton pump inhibitors and prostaglandins (misoprostol), this condition persists today 
in many patients who require NSAID therapy. Optimizing safety in these individuals, 
who often must take NSAID therapy for extended periods of time, is critical.5,7Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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Because of the significant adverse events associated with 
oral or systemic NSAIDs, it is imperative to seek pharmaco-
logic options with more favorable benefit-risk ratios. Safety 
concerns are even greater in special populations, such as 
older adults and those with gastrointestinal, cardiovascular, 
or renal risk factors. Therefore, the issue of reducing systemic 
exposure has special relevance in such populations.8 This 
article reviews recent studies evaluating the relative safety 
of oral NSAID formulations and strategies for balancing the 
risks of NSAIDs against their well established efficacy in 
individuals with osteoarthritis.
Mechanisms of action and available 
formulations
The analgesic, anti-inflammatory, and antipyretic effects 
of NSAIDs are a result of the ability of these agents to 
inhibit cyclo-oxygenase (COX) enzymes, which catalyze 
the conversion of arachidonic acid to prostaglandins, which 
are fatty acids involved in the generation of pain, fever, and 
inflammation.7,9 Currently available NSAIDs can be divided 
into two categories, ie, nonselective NSAIDs, which inhibit 
both COX-1 and COX-2, and COX-2 selective NSAIDs.
The COX-1 isoenzyme is widely and constitutively 
expressed in many tissues.9,10 It plays an important role in 
renal and gastrointestinal function, and is located on mono-
cytes and platelets, in the endothelium, and on renal collect-
ing tubules and seminal vesicles.9 These expression patterns 
explain the gastrointestinal and renal adverse events observed 
with the use of nonselective NSAIDs, in that COX-1 inhi-
bition reduces the cytoprotective effects of this enzyme on 
gastrointestinal function and renal physiology.9 Furthermore, 
COX-1 inhibition prevents the formation of proaggregatory 
thromboxane A2, which can result in decreased platelet 
aggregation, and thereby occlusive thrombi, but also can 
lead to excessive bleeding.9,11
In contrast with COX-1, the COX-2 isoenzyme is pre-
dominantly involved in pathophysiologic states, such as 
inflammation and tumorigenesis, and appears substantially 
more prevalent in injured or inflamed tissues.9,10 Found in 
higher concentrations in the kidney, brain, and reproduc-
tive organs, COX-2 is mainly expressed in parenchymal 
cells.10 COX-2 inhibition suppresses some inflammatory 
mediators involved in the progression of atherogenesis 
and ischemic myocardial damage, and appears to alter the 
balance between antithrombotic prostacyclin and prothrom-
botic thromboxane A2, increasing the risk of thrombosis.9,11 
COX-2 selective NSAIDs, notably celecoxib, have a 
recognized dose-related risk of cardiovascular events, but 
nonselective NSAIDs, such as diclofenac or ibuprofen, also 
confer cardiovascular risk.12
Oral NSAID therapy in 
osteoarthritis: key safety issues
The most ubiquitous and problematic adverse event associ-
ated with oral (systemic) NSAIDs is gastropathy, which 
confers a significant risk of decreased work time, disability, 
and medical costs. Increased risk of mortality from gastroin-
testinal bleeding, stomach, and bowel perforations is also of 
significant concern. Thus, although cardiovascular and renal 
vascular complications pose significant risks, they are com-
paratively less frequent than gastrointestinal complications. 
All three categories of events are associated with significant 
morbidity and mortality, and necessitate careful selection of 
patients for oral NSAID therapy to minimize risk.
Gastrointestinal adverse events
The most common adverse events associated with oral 
(systemic) NSAID therapy are those of the gastrointestinal 
system.13 A recent international, multicenter study of 3293 
consecutive candidates for NSAID treatment of osteoarthritis 
showed that 86.6% were at increased gastrointestinal risk, 
and 22.3% were considered at high risk for gastrointestinal 
events.14 The risk of gastric events increases with age, ris-
ing precipitously at age 60 years.15 Additional risk factors 
for gastrointestinal toxicity include history of ulcers (par-
ticularly bleeding ulcers), high NSAID dose, Helicobacter 
pylori infection (which increases ulcer risk by approximately 
1.8-fold), and concurrent use of antiplatelet agents and 
aspirin, both of which are commonly used by older adults.15 
NSAIDs and H. pylori have synergistic effects on risk; in 
a meta-analysis of 16 studies involving 1625 NSAID users, 
the odds ratio (OR) for peptic ulcer disease in H. pylori-
positive NSAID users was 61.1 (95% confidence interval [CI] 
9.98–373), compared with H. pylori-negative nonusers.16
Both nonselective and COX-2 selective NSAIDs are 
associated with some elevated gastrointestinal risk. However, 
the risk is significantly greater for nonselective NSAIDs.13,17 
Oral nonselective NSAIDs can cause serious upper and lower 
gastrointestinal effects, including bleeding, perforation, 
obstruction, stricture, anemia, and hypoalbuminemia.8 Of 
patients receiving nonselective NSAID therapy, 10%–30% 
develop peptic ulcers;13 a study in more than 2000 patients 
hospitalized for peptic ulcer demonstrated that the mortality 
rate in patients using nonselective NSAIDs was approxi-
mately 35%, and was double the rate of that in patients not 
taking NSAIDs.17 More common gastrointestinal adverse Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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events, occurring in 5%–20% of NSAID-treated patients, 
include dyspepsia, diarrhea, and other gastric disturbances. 
Dyspeptic symptoms do not always correlate with develop-
ment of ulcers, which in many cases have no discernible 
symptoms.5,13 Although associated with lower morbidity and 
mortality than perforations, ulcers, and bleeds, dyspeptic 
symptoms are distressing to many patients, frequently lead-
ing to costly symptomatic therapies and diagnostic studies, 
and may negatively affect adherence.13
Current measures to reduce the risk of gastrointestinal 
events when using oral NSAID therapy include concomitant 
use of agents such as misoprostol, as well as agents from the 
proton pump inhibitor class to suppress NSAID-associated 
increases in gastric acid secretion.13 Data from comparative 
studies have demonstrated that proton pump inhibitors are 
therapeutically superior to misoprostol, a prostaglandin E1 
analog, for this purpose.13,18 A strong evidence base exists for 
use of proton pump inhibitors with NSAIDs to protect against 
both short-term and long-term gastrointestinal effects.13 For 
example, in one study in which a proton pump inhibitor 
was added to naproxen plus low-dose (cardioprophylactic) 
aspirin, endoscopic findings were comparable with those in 
patients on treatment with celecoxib plus low-dose aspirin.19 
However, long-term use of proton pump inhibitors is also 
associated with risks, including a dose-related increase in 
risk of osteoporotic hip fractures among older adults.20 As 
with other multidrug regimens, the addition of a proton pump 
inhibitor to NSAID-based therapy increases the cost to the 
patient, as well as the risk of nonadherence.5,21 Nonadherence 
to proton pump inhibitors among patients receiving oral 
NSAID therapy is particularly problematic, because the most 
serious gastric adverse events associated with oral NSAID 
therapy are often asymptomatic.5,13 Patients with no symp-
toms may assume that the proton pump inhibitor is unneces-
sary and may be more likely to be noncompliant, when they 
may be at high risk for gastrointestinal bleeding.
In addition to direct drug costs and adherence, gas-
tropathy adds increased costs to the health care system.22 
It is estimated that more than 100,000 hospitalizations and 
10,000–20,000 deaths each year in the US can be attributed 
to NSAID-related complications.23 The costs of excess hos-
pitalizations have been estimated at $4 billion annually,24 not 
to mention the indirect costs of NSAID gastropathy, such as 
lost productivity.25 Oral NSAIDs are likely to have more cost 
associated with adverse events than topical NSAIDs.26 In a 
randomized trial by Castelnuovo et al comparing the cost-
effectiveness of topical and oral ibuprofen for knee pain, the 
total cost of drugs was lower in the topical group. The initial 
lower cost of oral NSAID therapy was displaced by the higher 
cost of other drugs to treat gastrointestinal and cardiovascular 
side effects.27 Rahme et al conducted a literature review to 
summarize data that evaluated the direct costs of NSAID-
related gastrointestinal adverse effects worldwide. The results 
showed that the events attributable to nonselective NSAIDs 
were substantial and that their costs far exceeded the cost of 
the nonselective NSAID itself.28
The level of gastrointestinal risk varies with the specific 
oral NSAID used. Agents with long half-lives, such as 
piroxicam, are associated with greater risk of gastrointesti-
nal bleeding and perforation because, in the face of lower 
renal excretion in the elderly, cumulative systemic NSAID 
exposure is much greater over time.29 Patient factors also 
modulate risk, in that older adults, especially those with 
a history of ulcers or concurrent use of aspirin, steroids, or 
anticoagulants, are at increased risk for these gastrointestinal 
events.5,8 The shrunken gastric microvasculature in older 
individuals increases their risk for ulcer bleeds, even in the 
absence of other risk factors.5 The risk of gastrointestinal 
adverse events can be reduced by the use of COX-2 selective 
agents, although their selectivity and impact on overall risk 
diminishes at increased doses.30,31 In addition, these agents 
are themselves associated with adverse effects, such as an 
increased risk of thrombotic cardiovascular events.32,33
Cardiovascular adverse events
Both COX-2 selective and nonselective oral (systemic) 
NSAIDs confer significant cardiovascular risks, although 
these events occur far less frequently compared with 
gastropathy.2,12,34 It has been postulated that the cardio-
vascular effects of NSAIDs result from an imbalance 
between the effects of thromboxane and prostacyclin on the 
endothelium.8 Based on the relative rates of cardiovascular 
adverse events with oral NSAIDs, five characteristics have 
emerged as key mediators of cardiovascular risk potential, 
ie, COX-2 selectivity, dose, longer plasma half-life, effect 
on blood pressure, and interaction with concomitant aspirin 
that may potentially reduce the cardioprotective (antiplatelet) 
effects of the drug.34
Rofecoxib, a COX-2 selective agent, was withdrawn from 
the global market in 2004 after it was shown to increase the 
risk of acute myocardial infarction and other cardiovascular 
events significantly.8 Level of risk varies among the oral 
NSAIDs that remain on the market, including nonselective 
NSAIDs. Data from a study that evaluated cardiovascular 
outcomes in Medicare patients who were receiving oral 
NSAID therapy demonstrated that, among the nonselective Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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NSAIDs, ibuprofen was associated with the highest rate 
of adverse cardiovascular outcomes (11.7 per 100 person-
years), followed by diclofenac (9.3 per 100 person-years), 
and naproxen (8.5 per 100 person-years).35
Renal adverse events
In addition to gastrointestinal and cardiovascular risks, all oral 
NSAIDs also confer a serious risk of renal adverse events.3 
Although comparative data are limited, some studies suggest 
that fenoprofen and indomethacin may have greater nephro-
toxicity than the other nonselective NSAIDs.3 Renal adverse 
events associated with oral NSAIDs include electrolyte reten-
tion, reduced glomerular filtration, nephritic syndrome, renal 
papillary necrosis, hyperkalemia, and chronic renal failure.3 
Although renal adverse events related to NSAIDs are rare in 
the population at large, their likelihood increases dramatically 
in high-risk patients, such as older adults, especially those 
with concurrent conditions, including underlying volume 
depletion, renal insufficiency, congestive heart failure, and 
diabetes.3 Significant increases in blood urea nitrogen and 
creatinine clearance have been observed in older patients, 
even after discontinuation of NSAIDs.3
Osteoarthritis guidelines
The adverse events associated with use of oral (systemic) 
NSAIDs are well established and have been studied in both 
clinical and observational trials. Guidelines for the manage-
ment of osteoarthritis provide suggestions for minimizing 
the risks of oral NSAID use. The American Geriatrics Soci-
ety guidelines recommend that nonselective NSAIDs and 
COX-2 selective NSAIDs be used rarely and with extreme 
caution, only in patients who have been carefully selected 
to minimize risk of gastrointestinal, cardiovascular, or renal 
adverse events, and only when safer alternative therapies 
have failed.36 These guidelines caution that older individu-
als taking nonselective NSAIDs and individuals on aspirin 
therapy taking COX-2 selective agents should take a proton 
pump inhibitor or misoprostol for gastroprotection. The 
American College of Gastroenterology cautions against the 
use of oral NSAID therapy in patients at high risk for gas-
trointestinal bleeding, even in conjunction with misoprostol 
and a proton pump inhibitor, and strongly recommends that 
safer alternatives to oral NSAID therapy be utilized.37 The 
American Academy of Orthopedic Surgeons guidelines sug-
gest that patients with symptomatic osteoarthritis of the knee 
and increased gastrointestinal risk (age $60 years, comorbid 
medical conditions, history of peptic ulcer disease, history of 
gastrointestinal bleeding, concurrent use of corticosteroids, 
and/or anticoagulants) receive one of the following analgesics 
for pain: acetaminophen (not to exceed 4 g/day), a topical 
NSAID, a nonselective oral NSAID plus a gastroprotective 
agent, or a COX-2 inhibitor.38
Topical NSAIDs in osteoarthritis: 
potential for risk reduction
Nonselective NSAIDs are available as oral formulations 
which produce systemic levels of drug and as topical formula-
tions which deliver drug to the local target tissue and result 
in significantly lower levels of systemic absorption relative 
to oral therapy.7 Whereas plasma drug concentrations after 
administration of topical NSAIDs are comparatively low 
(generally ,10% of that after oral administration), local drug 
concentrations in target tissues are high.7,39 Lower plasma 
concentrations of active drug after application of topical 
NSAIDs appear to be associated with a lower risk of systemic 
adverse events compared with oral formulations.39 However, 
data vary among the available topical agents. Only diclofenac 
topical solution has been compared with oral diclofenac in 
head-to-head trials, in which diclofenac topical solution estab-
lished comparable efficacy and a lower incidence of systemic 
adverse events compared with oral diclofenac.40,41
Topical diclofenac, in gel and solution formulations, is 
the only topical NSAID currently approved by the Food and 
Drug Administration for the management of osteoarthritis.42,43 
Although other topical salicylates are available over the coun-
ter to treat joint pain and were recommended in the American 
College of Rheumatology guidelines in 2000, these agents 
do not have the evidence base of diclofenac to support their 
use, possibly because of poor skin penetration properties,2,42,43 
and being nonacetylated salicylates with absent prostaglandin 
inhibition, they are weak analgesics.44
In clinical practice, topical NSAIDs are used for the many 
patients with osteoarthritis who require NSAID therapy 
but desire or need to minimize the risk of systemic adverse 
events or who prefer topical to oral dosing.42,45 A recent 
review by Haroutiunian et al reported that the incidence of 
severe gastrointestinal adverse events is three times lower 
with topical diclofenac compared with oral diclofenac, and 
that its systemic effects across the board were generally 
infrequent and did not differ from placebo in the great major-
ity of trials.7 Another recent systematic review by Makris 
et al evaluated the safety of topical NSAIDs in older adults 
with osteoarthritis. These authors concluded that the use of 
topical NSAIDs resulted in fewer severe gastrointestinal 
adverse events compared with oral NSAIDs in older adults.46 
Both of these reviews included data from a wide range of Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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topical NSAID preparations, including agents not currently 
  available in the US.7,46
In the US, diclofenac is available topically as a gel and as a 
solution for the management of osteoarthritis.42,43 A number of 
placebo-controlled studies have examined the safety and efficacy 
of these two topical diclofenac formulations individually.
Topical diclofenac solution  
with dimethylsulfoxide
Several randomized controlled trials have shown that topi-
cal diclofenac solution with a dimethylsulfoxide penetration 
enhancer (Pennsaid®, Mallinckrodt Inc, Hazelwood, MO) 
is effective and well tolerated in the treatment of signs and 
symptoms of knee osteoarthritis. Three vehicle-controlled 
studies, ranging in length from 4–12 weeks, established the 
ability of topical diclofenac solution to improve pain scores, 
physical function, patient global assessment, stiffness, and 
pain on walking.47–49 The most common adverse events 
were local skin irritation, such as dryness.47–49 Skin dryness 
may be due to the potential of dimethylsulfoxide to dissolve 
skin lipids, and may be countered by the application of skin 
emollients. However, the effect of emollients on skin dryness 
has not been specifically evaluated.40
Topical diclofenac solution is also unique among the 
diclofenac formulations available in the US, in that it has 
been compared with oral diclofenac in head-to-head trials 
including osteoarthritis of the knee. In two 12-week active-
controlled studies comparing topical diclofenac solution 
with oral diclofenac, topical diclofenac produced pain relief 
in patients with osteoarthritis comparable with pain relief 
experienced with oral diclofenac.40,41 In addition, topical 
diclofenac solution was associated with fewer systemic 
adverse events compared with oral diclofenac. In a study by 
Tugwell et al, patients treated with topical diclofenac solution 
had a significantly lower incidence of gastrointestinal adverse 
events compared with patients receiving oral diclofenac, 
including dyspepsia (15% versus 26%, P = 0.001), abdomi-
nal pain (12% versus 22%, P = 0.0008), nausea (8% versus 
13%, P = 0.04), and diarrhea (9% versus 17%, P = 0.001).41 
Incidence of abnormal liver function (aspartate transami-
nase, 2% versus 10%, P = 0.0001; alanine transaminase, 5% 
versus 17%, P , 0.0001) and altered laboratory parameters 
(eg, creatinine clearance, an indicator of renal effects) also 
occurred less frequently with topical diclofenac solution.41
Topical diclofenac solution demonstrated similar safety 
advantages in a study by Simon et al, in which only 6.5% of 
patients treated with topical diclofenac solution   experienced 
gastrointestinal adverse events, compared with 23.8% of 
those receiving oral diclofenac (dyspepsia, 2.6% versus 4.0%; 
abdominal pain, 3.2% versus 7.3%; nausea, 0% versus 2.0%; 
diarrhea, 1.3% versus 4.6%).40 The incidence of cardiovas-
cular events was comparably low among patients receiving 
oral diclofenac and treated with topical diclofenac solution 
(,2%), as was the incidence of hypertension (1.3%).40 Very 
large, longer-term studies would likely be needed to detect a 
difference in the incidence of cardiovascular effects between 
topical diclofenac solution and oral diclofenac therapy.
Topical diclofenac gel
Diclofenac gel 1% (Voltaren® gel, Endo Pharmaceuticals 
Inc, Chadds Ford, PA) has been studied in placebo-controlled 
studies to determine efficacy and safety in the treatment of pain 
associated with osteoarthritis. Diclofenac gel was significantly 
more effective than placebo in three studies (one 3-week and 
two 12-week), as would be expected.50–52 In all three trials, 
the incidence of gastrointestinal adverse events was similar 
between patients treated with diclofenac gel (ranging from 
0% to 5.9%)  and patients treated with placebo (ranging from 
1.7% to 5.0%).50–52 One study noted a higher incidence of 
cardiovascular events among patients treated with diclofenac gel 
compared with placebo (four events versus one event), although 
these events were deemed unrelated to treatment.51 The rates 
of gastrointestinal adverse events occurring in these studies 
of diclofenac gel are substantially lower than those with oral 
diclofenac treatment in other trials including osteoarthritis.40,41 
Observed discontinuation rates due to adverse reactions 
were only slightly higher for diclofenac gel versus placebo   
(5% versus 3%).53 The most common cause for discontinuation 
was application site reactions.53 The incidence of adverse events 
demonstrated in a long-term trial (up to 1 year) was similar to 
incidence in the placebo-controlled studies.53 In this long-term 
trial, application site dermatitis was observed in 11% of patients 
and led to discontinuation for 6% of patients.53
Summary
Osteoarthritis remains a prevalent yet too often unsafely 
treated disease, due to the well documented, systemic adverse 
events associated with the ubiquitous use of oral (systemic) 
NSAID therapy.8,13 It is estimated that almost half of the adult 
population may develop symptomatic osteoarthritis of the 
knee by the age of 85 years.54 Oral NSAIDs, widely used in 
the treatment of osteoarthritis, are associated with significant 
gastrointestinal adverse events, which the introduction of 
COX-2 selective NSAIDs has not completely eliminated.3,13 
NSAID gastropathy remains a silent threat, despite various 
efforts to manage it. The frequent gastric complications have Clinical Interventions in Aging 2011:6 submit your manuscript | www.dovepress.com
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introduced a tremendous cost burden due to the widespread 
chronic use of systemic NSAIDs in the elderly.55 In addition 
to gastrointestinal adverse events, oral nonselective NSAID 
therapy and treatment with COX-2 selective agents also 
increase the risk of cardiovascular events in a dose-dependent 
manner.12
Therefore, clinicians need strategies to reduce the risk 
of NSAID-related systemic adverse events as part of an 
overall approach to the management of osteoarthritis. One 
important possible risk-reduction strategy is the use of 
topical NSAIDs, which have been shown to be effective in 
osteoarthritis, but with a generally reduced risk of systemic 
adverse events compared with oral NSAIDs.48 All of the 
topical NSAIDs available in the US contain diclofenac 
and vary in formulation, use of penetration enhancers, and 
evidence base to support their use. Only topical diclofenac 
solution has been studied in direct comparison with oral 
diclofenac. In these studies, topical diclofenac solution 
exhibited comparable efficacy and a reduced incidence of 
systemic adverse events versus oral diclofenac.40,41 Several 
reviews and meta-analyses have shown topical NSAIDs to 
have significant safety advantages to minimize gastrointes-
tinal risk while improving tolerability in high-risk patients. 
Rates of gastrointestinal adverse events and ulcers, perfora-
tion, or bleeding have been much higher with oral nonse-
lective NSAIDs and celecoxib than with topical diclofenac 
formulations.52,56,57 In addition, there have been two studies 
in patients with osteoarthritis of the knee showing simi-
lar efficacy between topical diclofenac solution and oral 
diclofenac. Additional head-to-head studies in patients with 
osteoarthritis are needed to determine whether diclofenac 
gel performs similarly relative to oral diclofenac.
Because of the differences in evidence base and in 
potential, as yet unknown, differences in actual efficacy and 
systemic adverse events among the topical diclofenac for-
mulations, generalizations about the relative risk of topical 
versus oral NSAIDs should be minimized in favor of specific 
discussion of the relevant risks of each topical diclofenac 
formulation. Due to their demonstrated efficacy, safety, and 
potential to reduce systemic adverse events when compared 
with oral NSAIDs, topical NSAIDs can be considered 
important additions to the armamentarium for the treatment 
of osteoarthritis.43 Future long-term studies on chronic use 
will likely reveal that topical NSAIDs are a safer alternative 
to oral systemic NSAIDs, and may relieve high-risk elderly 
patients from common gastrointestinal and cardiorenal 
NSAID-related adverse events, as well as diminish systemic 
NSAID levels in the elderly.
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